These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27391386)

  • 41. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and tolerability of available urate-lowering drugs: a critical review.
    Strilchuk L; Fogacci F; Cicero AF
    Expert Opin Drug Saf; 2019 Apr; 18(4):261-271. PubMed ID: 30915866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
    Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G; Panova E; Day R
    Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
    Jansen TL; Perez-Ruiz F; Tausche AK; Richette P
    Clin Rheumatol; 2018 Dec; 37(12):3159-3165. PubMed ID: 30244431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
    Chohan S
    J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
    Jackson G; Dalbeth N; Te Karu L; Winnard D; Gow P; Gerard C; Minko N
    N Z Med J; 2014 Oct; 127(1404):37-47. PubMed ID: 25331310
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resolution of massive tophaceous gout with three urate-lowering drugs.
    Mejía-Chew C; Torres RJ; de Miguel E; Puig JG
    Am J Med; 2013 Nov; 126(11):e9-10. PubMed ID: 23978312
    [No Abstract]   [Full Text] [Related]  

  • 55. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    Kim JW; Kwak SG; Park SH
    Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
    [No Abstract]   [Full Text] [Related]  

  • 59. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal handling of urate in a patient with familial juvenile gouty nephropathy.
    Hisatome I; Kosaka H; Ohtahara K; Tsuboi M; Manabe I; Ohtahara A; Sawaguchi M; Igawa O; Tanaka Y; Fujimoto Y; Yoshida A; Takeda A; Shigemasa C
    Intern Med; 1996 Jul; 35(7):564-8. PubMed ID: 8842764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.